Sangamo/Pfizer are catching up to BioMarin and Spark with a gene therapy for hemophilia A — can they leapfrog ahead?
Sangamo researchers and their partners at Pfizer may be playing catch-up with BioMarin and Spark/Roche in developing a gene therapy to cure hemophilia A, but they’re off to an encouraging start.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.